Hikma Pharmaceuticals, a leading multinational pharmaceutical group, has signed an exclusive license agreement with specialty pharmaceutical company Azanta for its proprietary cancer product Nimoral (nimorazole).
Hikma Pharmaceuticals, a fast growing multinational pharmaceutical group, provided insights on the impact of recent societal, political and economic developments on growth markets in the Arab world at the recently concluded World Economic Forum
Hikma Pharmaceuticals, a leading medical group in the region, has signed an agreement with Boehringer Ingelheim Group of Companies to acquire the assets of Bedford Laboratories for $300 million.
Hikma is a fast growing multination
Jordan's Hikma Pharmaceuticals has formed a joint venture with Sheikh Mohammed Hussein Al Amoudi's Midroc Group to enter the Ethiopian healthcare market, where health spending is likely to more than doubl
Jordan-based Hikma Pharmaceuticals said it is reviewing options for its lucrative injectables business after receiving several unsolicited expressions of interest, driving up its shares nearly 8 per cent to a life-high.
UK-based Hikma Pharmaceuticals, a fast growing global pharmaceutical group, has posted revenue of $532.3 million for the first half of the year, marking a 34.8 per cent increase over the same period last year.
The group, with sales in m
Hikma Pharmaceuticals has partnered with Germany-based drug development firm Ergomed in an agreement that see Ergomed manage clinical trials for one of Hikma’s key anti-cancer products in Jordanian hospitals.
In turn, Hikma will provide Er